Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSP-1014.OX dose-finding and proof-of-concept study in major depressive disorder
ISRCTN31103960Phase 2Completed
- Sponsor
- Clerkenwell Health
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MSP-1014 in major depressive disorder (MDD) (5 arms), sponsored by Clerkenwell Health. Primary endpoints: Safety and cardiovascular tolerability and Change in depressive symptoms by MADRS. Started Mar 2023; status: completed.
02
Drugs
MSP-1014
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN31103960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN31103960.